Colorectal Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLR109 MIFTS: 54	Colorectal Adenocarcinoma Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma ¹² ¹⁵ ¹⁷

Adenocarcinoma of Large Intestine ⁷⁴

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050861

EFO ¹⁷ EFO_0000365

UMLS ⁷⁴ C1319315

Sources

Summaries for Colorectal Adenocarcinoma

Disease Ontology : ¹² A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to adenocarcinoma and colorectal adenoma. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are Developmental Biology and fMLP Pathway. The drugs Iron and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lung, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	31.2	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
2	colorectal adenoma	31.1	CTNNB1 HRAS KRAS MLH1 MSH2 TP53
3	gastrointestinal stromal tumor	30.6	BRAF EGFR KRAS TP53
4	renal cell carcinoma, nonpapillary	30.2	CDH1 EGFR KRT20 KRT7
5	chordoma	30.2	CDH1 EGFR KRT7
6	villous adenoma	30.1	BRAF CDX2 KRAS KRT20
7	mucinous bronchioloalveolar adenocarcinoma	30.0	CDX2 KRT20 KRT7
8	adenoma	29.8	BRAF CTNNB1 KRAS MLH1 MSH2 TP53
9	mucinous adenocarcinoma	29.6	CDX2 EGFR KRAS KRT20 KRT7 MLH1
10	lynch syndrome	29.6	BRAF CTNNB1 EGFR KRAS MLH1 MSH2
11	bladder adenocarcinoma	29.5	CDX2 CTNNB1 HRAS KRT20 KRT7
12	familial adenomatous polyposis	29.4	CDH1 CTNNB1 KRAS MLH1 MSH2 TP53
13	squamous cell carcinoma	29.4	BRAF CDH1 CTNNB1 EGFR HRAS TP53
14	intrahepatic cholangiocarcinoma	29.0	CDH1 CDX2 CTNNB1 EGFR KRAS KRT20
15	hepatocellular carcinoma	28.8	CDH1 CEACAM5 CTNNB1 EGFR HRAS KRAS
16	esophageal cancer	28.7	CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
17	cholangiocarcinoma	28.6	BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
18	lung cancer	28.5	BRAF CDH1 CEACAM5 EGFR HRAS KRAS
19	lung cancer susceptibility 3	28.2	BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
20	gastric adenocarcinoma	28.0	BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
21	intestinal disease	28.0	CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
22	colorectal cancer	27.9	AURKA BRAF CDH1 CDX2 CEACAM5 CTNNB1
23	bladder squamous cell carcinoma	10.6	BRAF TP53
24	nevus of ota	10.6	BRAF TP53
25	rare adenocarcinoma of the breast	10.6	KRAS TP53
26	vulvar intraepithelial neoplasia	10.5	KRT7 TP53
27	seminal vesicle adenocarcinoma	10.5	KRT20 KRT7
28	transverse colon cancer	10.5	KRT20 KRT7
29	colloid adenoma	10.5	KRT20 TP53
30	papillary transitional carcinoma	10.5	KRT20 KRT7
31	cystic basal cell carcinoma	10.5	KRT20 KRT7
32	malignant syringoma	10.5	KRT20 KRT7
33	eyelid carcinoma	10.5	KRT20 KRT7
34	krukenberg carcinoma	10.5	KRT20 KRT7
35	small cell carcinoma of the bladder	10.5	KRT20 KRT7
36	ovary neuroendocrine neoplasm	10.5	CDX2 KRT7
37	vaginal benign neoplasm	10.5	CDX2 KRT20
38	vaginal adenoma	10.5	CDX2 KRT20
39	vaginal tubulovillous adenoma	10.5	CDX2 KRT20
40	cerebral convexity meningioma	10.5	CDH1 TP53
41	renal pelvis adenocarcinoma	10.5	CDH1 KRT7
42	benign breast adenomyoepithelioma	10.5	EGFR KRT7
43	brain ependymoma	10.5	EGFR TP53
44	oncocytic breast carcinoma	10.5	EGFR KRT7
45	intracranial chondrosarcoma	10.5	CEACAM5 TP53
46	cutaneous mucoepidermoid carcinoma	10.5	CEACAM5 KRT7
47	anal gland adenocarcinoma	10.5	CEACAM5 KRT7
48	anal paget's disease	10.5	CDX2 CEACAM5
49	adult hepatocellular carcinoma	10.4	CTNNB1 TP53
50	ovarian clear cell carcinoma	10.4	KRAS KRT7 TP53

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:

Sources

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

²⁷ (show all 16)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.92	AURKA EGFR HRAS KRAS PIM2 BRAF
2	Decreased viability	GR00106-A-0	10.92	KRAS
3	Decreased viability	GR00173-A	10.92	CDK8
4	Decreased viability	GR00221-A-1	10.92	AURKA CDH1 CDK8 EGFR HRAS KRAS
5	Decreased viability	GR00221-A-2	10.92	AURKA CDK8 HRAS KRAS
6	Decreased viability	GR00221-A-3	10.92	HRAS
7	Decreased viability	GR00221-A-4	10.92	AURKA CDK8 EGFR BRAF
8	Decreased viability	GR00231-A	10.92	AURKA
9	Decreased viability	GR00301-A	10.92	CDH1 CDK8 KRAS PIM2 BRAF MSH2
10	Decreased viability	GR00381-A-1	10.92	KRAS BRAF
11	Decreased viability	GR00402-S-2	10.92	AURKA CDH1 CDK8 EGFR HRAS KRAS
12	Decreased cell migration	GR00055-A-1	9.97	AURKA BRAF CDK8 CTNNB1 EGFR HRAS
13	Decreased viability in esophageal squamous lineage	GR00235-A	9.93	AURKA BRAF CDH1 CDK8 CTNNB1 FABP6
14	Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection	GR00234-A-2	9.5	BRAF CDK8 EGFR
15	Increased cell migration	GR00055-A-3	9.43	AURKA BRAF CTNNB1 EGFR HRAS KRAS
16	Increased cell viability after pRB stimulation	GR00230-A-1	8.92	AURKA CDK8 EGFR PIM2

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

⁴⁷ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.31	AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
2	digestive/alimentary	MP:0005381	10.25	BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
3	homeostasis/metabolism	MP:0005376	10.23	BRAF CDH1 CDX2 CTNNB1 EGFR FABP6
4	mortality/aging	MP:0010768	10.21	AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
5	embryo	MP:0005380	10.19	AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
6	endocrine/exocrine gland	MP:0005379	10.18	BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
7	integument	MP:0010771	10.09	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
8	craniofacial	MP:0005382	10.07	BRAF CTNNB1 EGFR HRAS KRAS SATB2
9	neoplasm	MP:0002006	10.06	AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
10	limbs/digits/tail	MP:0005371	9.95	BRAF CDX2 CTNNB1 EGFR KRAS SATB2
11	no phenotypic analysis	MP:0003012	9.8	AURKA CDH1 CTNNB1 EGFR HRAS KRAS
12	pigmentation	MP:0001186	9.55	BRAF CTNNB1 EGFR KRAS TP53
13	renal/urinary system	MP:0005367	9.5	BRAF CTNNB1 EGFR HRAS KRAS KRT7
14	respiratory system	MP:0005388	9.23	BRAF CTNNB1 EGFR HRAS KRAS MLH1

Sources

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron

Approved, Experimental

Phase 4

7439-89-6, 15438-31-0

27284 23925

Hematinics

Phase 4,Phase 3,Phase 1,Phase 2

Hepcidins

Phase 4

Ferric Compounds

Phase 4

Iron Supplement

Phase 4

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Oxaliplatin

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

61825-94-3

43805 6857599 5310940 9887054

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

leucovorin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

58-05-9

143 6006

Levoleucovorin

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

68538-85-2

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

51-21-8

3385

Irinotecan

Approved, Investigational

Phase 2, Phase 3,Phase 1

100286-90-6, 97682-44-5

60838

Atezolizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1

1380723-44-3

Nicotine

Approved

Phase 3

54-11-5

89594 942

Panitumumab

Approved, Investigational

Phase 3,Phase 2

339177-26-3

50070211

Calcium

Approved, Nutraceutical

Phase 3,Phase 2

7440-70-2

271

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1

59-30-3

6037

Glutamic Acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Liver Extracts

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antineoplastic Agents, Immunological

Phase 3,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antidotes

Phase 3,Phase 2,Phase 1

Calcium, Dietary

Phase 3,Phase 2

Protective Agents

Phase 3,Phase 2,Phase 1

topoisomerase I inhibitors

Phase 2, Phase 3,Phase 1

Topoisomerase Inhibitors

Phase 2, Phase 3,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 1,Phase 2

Pharmaceutical Solutions

Phase 3,Phase 2

Vitamin B Complex

Phase 3,Phase 2,Phase 1

Trace Elements

Phase 3,Phase 2,Phase 1

Vitamins

Phase 3,Phase 2,Phase 1

Folate

Phase 3,Phase 2,Phase 1

Hormones

Phase 3,Phase 2,Phase 1

Vitamin B9

Phase 3,Phase 2,Phase 1

Nutrients

Phase 3,Phase 2,Phase 1

Micronutrients

Phase 3,Phase 2,Phase 1

Endothelial Growth Factors

Phase 3,Phase 2

Immunoglobulin G

Phase 3,Phase 2

Mitogens

Phase 3,Phase 2,Phase 1

Bone Density Conservation Agents

Phase 3,Phase 2

Tetrahydrofolates

Phase 3

Formyltetrahydrofolates

Phase 3

Mitomycins

Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 136)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravenous Iron: Measuring Response in Anemic Surgical Patients	Completed	NCT02057471	Phase 4	Intravenous ferric carboxymaltose
2	IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia	Completed	NCT01701310	Phase 4	Ferric carboxymaltose;Ferrous Sulphate
3	A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)	Completed	NCT02788279	Phase 3	Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
4	Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases	Completed	NCT00265356	Phase 3
5	A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer	Completed	NCT00623805	Phase 3	Bevacizumab;Capecitabine;Oxaliplatin
6	Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM	Recruiting	NCT03125161	Phase 3	HAI;chemotherapy ± target therapy
7	Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer	Recruiting	NCT02997228	Phase 3	Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
8	5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab	Recruiting	NCT03300609	Phase 3	Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
9	Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases	Recruiting	NCT02758951	Phase 2, Phase 3
10	Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）	Active, not recruiting	NCT02390947	Phase 3	Famitinib;Placebo
11	Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma	Not yet recruiting	NCT03708536	Phase 3	S-1;Bevacizumab;Capecitabine
12	TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)	Not yet recruiting	NCT03783559	Phase 3	TACE;chemotherapy±target therapy
13	Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma	Unknown status	NCT01552967	Phase 2	Capecitabine
14	Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.	Unknown status	NCT01067053	Phase 2	bevacizumab, capecitabine, oxaliplatin
15	Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma	Unknown status	NCT00075556	Phase 2	capecitabine
16	Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)	Unknown status	NCT01929616	Phase 2	regorafenib
17	Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00544011	Phase 2	capecitabine;fluorouracil;irinotecan hydrochloride
18	Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer	Unknown status	NCT00104689	Phase 2	capecitabine;oxaliplatin
19	Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00027833	Phase 2	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
20	Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma	Completed	NCT00034190	Phase 2	S-8184 Paclitaxel Injectable Emulsion
21	Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .	Completed	NCT02788006	Phase 2	Regorafenib 160 mg
22	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)	Completed	NCT01900717	Phase 2	LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
23	Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma	Completed	NCT00168155	Phase 2	perioperative chemotherapy
24	Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.	Completed	NCT02181465	Phase 2
25	Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma	Completed	NCT00574171	Phase 2	lapatinib;Capecitabine
26	DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma	Completed	NCT00080834	Phase 2	DJ-927
27	Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy	Completed	NCT00419159	Phase 2	Everolimus (RAD001)
28	Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus	Completed	NCT00597506	Phase 2	Bevacizumab;Everolimus
29	Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma	Completed	NCT00165217	Phase 2	Capecitabine;Thalidomide
30	Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas	Completed	NCT01730586	Phase 2	Abraxane
31	Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib	Completed	NCT00582660	Phase 2	Celecoxib;Placebo
32	Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer	Completed	NCT00003220	Phase 2	bryostatin 1
33	Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer	Completed	NCT00025350	Phase 2	gefitinib
34	Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone	Completed	NCT00890305	Phase 2	CT-011;FOLFOX
35	Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver	Completed	NCT00149396	Phase 1, Phase 2	NV1020
36	1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer	Completed	NCT01417494	Phase 2	Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
37	Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer	Completed	NCT00123851	Phase 2	Tarceva (OSI-774);Capecitabine;Oxaliplatin
38	Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy	Completed	NCT01225744	Phase 2	Cetuximab;Irinotecan;Oxaliplatin;UFT
39	Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed	Completed	NCT00259844	Phase 2
40	Azacitidine and CAPOX in Metastatic Colorectal Cancer	Completed	NCT01193517	Phase 1, Phase 2	Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
41	Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma	Recruiting	NCT01844076	Phase 1, Phase 2	Phase I (Quinacrine);Capecitabine
42	Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma	Recruiting	NCT03559543	Phase 2
43	FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation	Recruiting	NCT03584711	Phase 2
44	Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases	Recruiting	NCT03599752	Phase 2	Chemotherapy
45	Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases	Recruiting	NCT02185443	Phase 2
46	Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer	Recruiting	NCT03642067	Phase 2	Nivolumab;Relatlimab
47	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC	Recruiting	NCT03442569	Phase 2	Panitumumab;Nivolumab;Ipilimumab
48	Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer	Recruiting	NCT01053013	Phase 2
49	Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer	Recruiting	NCT03475004	Phase 2	Pembrolizumab, Bevacizumab, and Binimetinib
50	A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors	Recruiting	NCT02599324	Phase 1, Phase 2	ibrutinib;everolimus;docetaxel;paclitaxel;cetuximab

Search NIH Clinical Center for Colorectal Adenocarcinoma

Sources

Genetic Tests for Colorectal Adenocarcinoma

Sources

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

⁴²

Liver, Colon, Lung, Breast, Lymph Node, Appendix, Bone

Sources

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 974)

#	Title	Authors	Year
1	Prognosis of three histological subtypes of colorectal adenocarcinoma: A retrospective analysis of 8005 Chinese patients. ( 31074597 )	Li C...Zhu J	2019
2	Response to "histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by lynch syndrome"-reply. ( 31075301 )		2019
3	Response to "histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by lynch syndrome". ( 31077684 )	Georgiou D...Monahan K	2019
4	Cancer in a bang: panel next-generation gene sequencing and OncoScan array analysis of a minute colorectal adenocarcinoma and its precursor adenoma. ( 31087409 )	H?hns M...Prall F	2019
5	Expression profile of genes associated with the proteins degradation pathways in colorectal adenocarcinoma. ( 31096896 )	Martyna B...Janikowska G	2019
6	LETM1 is a potential cancer stem-like cell marker and predicts poor prognosis in colorectal adenocarcinoma. ( 31101574 )	Piao L...Xuan Y	2019
7	LINC01638 silencing inhibits cancer cell proliferation in colorectal adenocarcinoma through interaction with RUNX2. ( 31059049 )	Zhuo W...Zhang T	2019
8	Metastatic Colorectal Adenocarcinoma in a Bifid Ureter. ( 30989122 )	Gopal N...Eshghi M	2019
9	Id-1 expression in colorectal adenocarcinoma tissues and its clinical significance. ( 30994840 )	Wu XL...Liu B	2019
10	Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome? ( 30920041 )	Leong RWL...Wasinger VC	2019
11	Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply. ( 30920043 )	Keshteli AH...Dieleman LA	2019
12	Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply. ( 30920048 )	Bond A...Probert C	2019
13	Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. ( 30922401 )	Luo C...Wu W	2019
14	Tumor-to-Tumor Metastasis of Colorectal Adenocarcinoma to Ovarian Cystadenofibroma: A Case Report and Review of the Literature. ( 30882401 )	Fahoum I...Aizic A	2019
15	KRAS mutations in the parental tumour accelerate in vitro growth of tumoroids established from colorectal adenocarcinoma. ( 30884019 )	Mousavi N...Thastrup J	2019
16	Exposure to phthalate-containing prescription drugs and the risk of colorectal adenocarcinoma: A Danish nationwide case-control study. ( 30793813 )	Ennis ZN...Damkier P	2019
17	The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. ( 30466765 )	Cho J...Ha SY	2019
18	Evaluation of Peritumoral Fibrosis in Metastatic Colorectal Adenocarcinoma to the Liver Using Digital Image Analysis. ( 30339201 )	Waters KM...Anders RA	2019
19	Identification of LINC01234 and MIR210HG as novel prognostic signature for colorectal adenocarcinoma. ( 30362555 )	He Z...Zhang Z	2019
20	Hepatobiliary Iminodiacetic Acid Scanning Detects Previously Unknown Hepatic Metastases from Colorectal Adenocarcinoma. ( 30076243 )	Chapman J...Palka J	2019
21	Correlation study of GAPDH, Bcl-2, and Bax protein immunoexpression in patients with colorectal adenocarcinoma. ( 30581507 )	Brzozowa-Zasada M...St?plewska K	2018
22	PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. ( 30555542 )	Mai D...Lin D	2018
23	Down regulation of lncRNA MEG3 promotes colorectal adenocarcinoma cell proliferation and inhibits the apoptosis by up-regulating TGF-β1 and its downstream sphingosine kinase 1. ( 30556866 )	Dong X...Li SY	2018
24	Combined fibrinogen and neutrophil-lymphocyte ratio as a predictive factor in resectable colorectal adenocarcinoma. ( 30568490 )	Li X...Qin C	2018
25	Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma. ( 30505575 )	Jensen CE...Loaiza-Bonilla A	2018
26	Investigation of the Anticancer Mechanism of Isoorientin Isolated from Eremurus Spectabilis Leaves via Cell Cycle Pathways in HT-29 Human Colorectal Adenocarcinoma Cells. ( 30515037 )	Gundogdu G...Karaoglan ES	2018
27	Isolated bone marrow metastases of colorectal adenocarcinoma. ( 30414232 )	O'Brien JM...Proud D	2018
28	Worst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma. ( 30358195 )	Us?n PLS...Maluf FC	2018
29	GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma. ( 30321514 )	Yang Z...Xuan Y	2018
30	Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis. ( 30323980 )	Chen CH...Wu SY	2018
31	The Effect of LncRNA H19/miR-194-5p Axis on the Epithelial-Mesenchymal Transition of Colorectal Adenocarcinoma. ( 30278464 )	Li CF...Sun LB	2018
32	Computational analysis of mRNA expression profiles identifies a novel triple-biomarker model as prognostic predictor of stage II and III colorectal adenocarcinoma patients. ( 30214289 )	Cheng X...Hou D	2018
33	ARHGEF7 promotes metastasis of colorectal adenocarcinoma by regulating the motility of cancer cells. ( 30132516 )	Lei X...Li T	2018
34	Early detection of colorectal adenocarcinoma: a clinical decision support tool based on plasma porphyrin accumulation and risk factors. ( 30134852 )	Lualdi M...Leo E	2018
35	Expression of leptin in colorectal adenocarcinoma showed significant different survival patterns associated with tumor size, lymphovascular invasion, distant metastasis, local recurrence, and relapse of disease in the western province of Saudi Arabia. ( 30142858 )	Al-Maghrabi JA...Khabaz MN	2018
36	Additional lymphadenectomy might not improve survival of patients with resectable metastatic colorectal adenocarcinoma of T4 stage, proximal location, poor/undifferentiation, or N3/N4 stages: a large population-based study. ( 30026839 )	Zhou YY...Jin R	2018
37	SCF/c-KIT signaling promotes mucus secretion of colonic goblet cells and development of mucinous colorectal adenocarcinoma. ( 30034943 )	Li G...Zhou D	2018
38	Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma. ( 30061254 )	Lee YM...Kim KH	2018
39	Long Noncoding RNAs in Colorectal Adenocarcinoma; an in silico Analysis. ( 29948619 )	Ansari H...Asl JM	2018
40	Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors. ( 29950257 )	Nemanqani DM...Al-Sufyani WM	2018
41	Localized lymphoid hyperplasia of the spleen mimicking metastatic colorectal adenocarcinoma. ( 29952067 )	Huynh F...Smith M	2018
42	Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. ( 29955144 )	Papke DJ...Dong F	2018
43	In vivo identification of novel TGIF2LX target genes in colorectal adenocarcinoma using the cDNA-AFLP method. ( 29960902 )	Mobini GR...Heidari M	2018
44	Anatomical subsite can modify the association between meat and meat compounds and risk of colorectal adenocarcinoma: Findings from three large US cohorts. ( 29873077 )	Etemadi A...Sinha R	2018
45	SCF/c-KIT Signaling Increased Mucin2 Production by Maintaining Atoh1 Expression in Mucinous Colorectal Adenocarcinoma. ( 29786668 )	Shen P...Zhou D	2018
46	Colorectal Adenocarcinoma with an Alternative Serrated Pathway. ( 29805354 )	Eizuka M...Sugai T	2018
47	Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome. ( 29723603 )	Hemminger JA...Frankel WL	2018
48	Loss of BAP1 Expression Occurs Rarely to Never in Colorectal Adenocarcinoma. ( 28362705 )	Chui J...Gill AJ	2018
49	Clinical and Histopathologic Features of Colorectal Adenocarcinoma in Crohn's Disease. ( 28654553 )	Galata C...Horisberger K	2018
50	Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( 28819759 )	Pariente R...Espino J	2018

Sources

Genes for Colorectal Adenocarcinoma

Genes related to Colorectal Adenocarcinoma (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	FABP6	Fatty Acid Binding Protein 6	Protein Coding	29.46	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Functions (show sections)
2	AURKA	Aurora Kinase A	Protein Coding	27.64	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
3	FGFBP1	Fibroblast Growth Factor Binding Protein 1	Protein Coding	26.01	GeneCards inferred via : Publications Summaries (show sections)
4	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	25.7	GeneCards inferred via : Publications Variants (show sections)
5	TP53	Tumor Protein P53	Protein Coding	23.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	CDX2	Caudal Type Homeobox 2	Protein Coding	23.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	KRT7	Keratin 7	Protein Coding	23.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	23.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	22.79	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	MLH1	MutL Homolog 1	Protein Coding	22.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	KRT20	Keratin 20	Protein Coding	22.59	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	CDH1	Cadherin 1	Protein Coding	22.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	EGFR	Epidermal Growth Factor Receptor	Protein Coding	22.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	CTNNB1	Catenin Beta 1	Protein Coding	22.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	SATB2	SATB Homeobox 2	Protein Coding	22.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	MSH2	MutS Homolog 2	Protein Coding	21.97	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	PIM2	Pim-2 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	15.63	GeneCards inferred via : Functions Expressions (show sections)
18	CDK8	Cyclin Dependent Kinase 8	Protein Coding	14.41	GeneCards inferred via : Publications Variants (show sections)
19	CEACAM5	Carcinoembryonic Antigen Related Cell Adhesion Molecule 5	Protein Coding	13.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	C2orf68	Chromosome 2 Open Reading Frame 68	Protein Coding	12.35	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	11.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	11.69	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	CCND1	Cyclin D1	Protein Coding	11.68	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Colorectal Adenocarcinoma

Sources

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Sources

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)

#	Super pathways	Score	Top Affiliating Genes
1	Developmental Biology ⁶⁷ Show member pathways Axon guidance ⁶⁷	13.51	BRAF CDK8 CTNNB1 EGFR HRAS KRAS
2	fMLP Pathway ⁶⁵ Show member pathways Alpha-Adrenergic Signaling ⁶⁵ CCR3 Pathway in Eosinophils ⁶⁵ CXCR4 Pathway ⁶⁵ Huntington's Disease Pathway ⁶⁵ Internalin Pathway ⁶⁵ Signal transduction Activation of PKC via G-Protein coupled receptor ²³ VEGF and S-1P Signaling ⁶⁵	12.98	BRAF CDH1 CDX2 CTNNB1 HRAS KRAS
3	MAPK signaling pathway ¹ ³⁸	12.78	BRAF EGFR HRAS KRAS TP53
4	4-1BB Pathway ⁶⁵ Show member pathways CD27 Pathway ⁶⁵ CD40 Signaling ⁶⁵ CMV and MAPK Pathways ⁶⁵ NF-KappaB Activation by EBV ⁶⁵ NF-kappaB Activation by Viruses ⁶⁵ PKR Pathway ⁶⁵ SUMO Pathway ⁶⁵ TNFR2 Pathway ⁶⁵	12.7	BRAF EGFR HRAS KRAS TP53
5	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.7	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
6	Ras signaling pathway ³⁸ Show member pathways Rap1 signaling pathway ³⁸	12.69	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
7	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.69	BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
8	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.67	BRAF CDH1 CTNNB1 HRAS KRAS TP53
9	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.66	BRAF CDH1 EGFR HRAS KRAS TP53
10	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.6	BRAF EGFR HRAS KRAS TP53
11	Pathways in cancer ³⁸	12.58	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
12	DNA Damage ⁴	12.53	AURKA CDK8 MLH1 MSH2 TP53
13	Immune response IL-23 signaling pathway ²³ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁵ Development Angiopoietin - Tie2 signaling ²³ Development PDGF signaling via STATs and NF-kB ²³ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²³ Rac1/Pak1/p38/MMP-2 pathway ¹	12.53	CTNNB1 EGFR HRAS KRAS MSH2 TP53
14	mTOR signaling pathway (KEGG) ³⁸ Show member pathways mTOR Signaling Pathway ⁶⁶	12.52	BRAF EGFR HRAS KRAS TP53
15	Development EGFR signaling pathway ²³ Show member pathways Development ERBB-family signaling ²³ EGF Pathway ⁶⁵ EGFR Signaling Pathway ⁶⁸ ErbB receptor signaling network ¹	12.46	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
16	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.44	CTNNB1 EGFR HRAS KRAS TP53
17	Arrhythmogenic right ventricular cardiomyopathy (ARVC) ³⁸ Show member pathways Arrhythmogenic Right Ventricular Cardiomyopathy ¹ Calpain Protease Regulates Cellular Mechanics ⁶⁵	12.43	CTNNB1 EGFR HRAS KRAS
18	Development VEGF signaling via VEGFR2 - generic cascades ²³ Show member pathways Development VEGF signaling and activation ²³ VEGF - VEGF R2 Signaling Pathways ⁶⁶	12.41	BRAF CTNNB1 HRAS KRAS
19	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	12.38	BRAF CDH1 CTNNB1 EGFR HRAS KRAS
20	Human T-cell leukemia virus 1 infection ³⁸	12.36	CTNNB1 HRAS KRAS TP53
21	Signaling by FGFR2 ⁶⁷ Show member pathways FGFR2 ligand binding and activation ⁶⁷ FGFR2b ligand binding and activation ⁶⁷ Signaling by FGFR ⁶⁷	12.29	BRAF FGFBP1 HRAS KRAS
22	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²³ Show member pathways Activation of the AP-1 family of transcription factors ⁶⁷ Immune response Oncostatin M signaling via MAPK in human cells ²³ MAPK Cascade ¹ Oncostatin M Signaling Pathway ¹	12.27	BRAF HRAS KRAS TP53
23	Proteoglycans in cancer ³⁸	12.24	BRAF CTNNB1 EGFR HRAS KRAS TP53
24	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.21	BRAF EGFR HRAS KRAS TP53
25	mTOR Pathway ⁷³ Show member pathways Insulin Pathway ⁷³ TGF-beta Pathway ⁷³	12.19	BRAF HRAS KRAS TP53
26	NGF Pathway ⁶⁵ Show member pathways TRKA Signaling ⁶⁵	12.16	BRAF HRAS KRAS TP53
27	AKT Signaling Pathway ⁶⁸	12.15	EGFR HRAS KRAS TP53
28	EGF/EGFR Signaling Pathway ¹	12.12	AURKA BRAF EGFR HRAS KRAS
29	FoxO signaling pathway ³⁸ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.11	BRAF EGFR HRAS KRAS
30	Direct p53 effectors ¹	12.09	EGFR MLH1 MSH2 TP53
31	UVA-Induced MAPK Signaling ⁶⁵ Show member pathways UVB-Induced MAPK Signaling ⁶⁵	12.08	EGFR HRAS KRAS TP53
32	G12-G13 in Cellular Signaling ⁶⁵	12.04	CDH1 CTNNB1 HRAS KRAS
33	Thyroid hormone signaling pathway ³⁸	12	CTNNB1 HRAS KRAS TP53
34	DNA Damage Response (only ATM dependent) ¹	11.99	CTNNB1 HRAS KRAS TP53
35	Glioblastoma Multiforme ⁶⁵	11.93	BRAF CTNNB1 EGFR HRAS KRAS TP53
36	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants ⁶⁷ Show member pathways Constitutive Signaling by EGFRvIII ⁶⁷ Signaling by EGFR in Cancer ⁶⁷ Signaling by EGFRvIII in Cancer ⁶⁷ Signaling by Ligand-Responsive EGFR Variants in Cancer ⁶⁷	11.87	EGFR HRAS KRAS
37	Listeria monocytogenes entry into host cells ⁶⁷ Show member pathways E-cadherin signaling events ¹ EGFR downregulation ⁶⁷ InlA-mediated entry of Listeria monocytogenes into host cells ⁶⁷ InlB-mediated entry of Listeria monocytogenes into host cell ⁶⁷ Negative regulation of MET activity ⁶⁷	11.87	CDH1 CTNNB1 EGFR
38	Gap junction ³⁸	11.85	EGFR HRAS KRAS
39	VEGF Pathway (Tocris) ⁶² Show member pathways VEGF Pathway ⁷³	11.81	BRAF HRAS KRAS
40	Colorectal Cancer Metastasis ⁶⁵	11.78	BRAF CDH1 CTNNB1 EGFR KRAS MLH1
41	Platinum drug resistance ³⁸	11.76	MLH1 MSH2 TP53
42	Adherens junction ³⁸	11.75	CDH1 CTNNB1 EGFR
43	Mitophagy - animal ³⁸	11.7	HRAS KRAS TP53
44	Negative regulation of MAPK pathway ⁶⁷ Show member pathways RAF activation ⁶⁷	11.69	BRAF HRAS KRAS
45	Bladder cancer ¹ ³⁸	11.66	BRAF CDH1 EGFR HRAS KRAS TP53
46	Long-term depression ³⁸	11.65	BRAF HRAS KRAS
47	Central carbon metabolism in cancer ³⁸	11.65	EGFR HRAS KRAS TP53
48	Agrin Interactions at Neuromuscular Junction ⁶⁵	11.62	EGFR HRAS KRAS
49	DNA damage_Role of Brca1 and Brca2 in DNA repair ²³	11.55	HRAS KRAS MLH1 MSH2 TP53
50	Aryl Hydrocarbon Receptor ¹	11.54	EGFR HRAS KRAS

Sources

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	flotillin complex	GO:0016600	8.62	CDH1 CTNNB1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.92	BRAF CTNNB1 HRAS KRAS TP53
2	MAPK cascade	GO:0000165	9.88	BRAF EGFR HRAS KRAS
3	cell proliferation	GO:0008283	9.88	CTNNB1 EGFR HRAS PIM2 TP53
4	positive regulation of transcription, DNA-templated	GO:0045893	9.88	CDH1 CDX2 CTNNB1 EGFR PIM2 TP53
5	Ras protein signal transduction	GO:0007265	9.74	HRAS KRAS TP53
6	cellular response to drug	GO:0035690	9.73	BRAF EGFR TP53
7	positive regulation of cell proliferation	GO:0008284	9.73	CDX2 CTNNB1 EGFR FGFBP1 HRAS KRAS
8	positive regulation of MAP kinase activity	GO:0043406	9.69	EGFR HRAS KRAS
9	negative regulation of neuron apoptotic process	GO:0043524	9.62	BRAF HRAS KRAS MSH2
10	positive regulation of isotype switching to IgG isotypes	GO:0048304	9.59	MLH1 MSH2
11	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.58	EGFR TP53
12	entry of bacterium into host cell	GO:0035635	9.55	CDH1 CTNNB1
13	positive regulation of fibroblast growth factor receptor signaling pathway	GO:0045743	9.54	CTNNB1 FGFBP1
14	response to isolation stress	GO:0035900	9.49	HRAS KRAS
15	cellular response to indole-3-methanol	GO:0071681	9.46	CDH1 CTNNB1
16	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.43	MLH1 MSH2
17	negative regulation of cell proliferation	GO:0008285	9.43	CTNNB1 FABP6 FGFBP1 HRAS PIM2 TP53
18	somatic recombination of immunoglobulin gene segments	GO:0016447	9.37	MLH1 MSH2
19	negative regulation of apoptotic process	GO:0043066	9.17	AURKA BRAF CEACAM5 CTNNB1 EGFR PIM2
20	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.16	MLH1 MSH2

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase activity	GO:0004672	9.88	AURKA BRAF CDK8 EGFR PIM2
2	ATP binding	GO:0005524	9.86	AURKA BRAF CDK8 EGFR MLH1 MSH2
3	protein heterodimerization activity	GO:0046982	9.85	AURKA BRAF CTNNB1 EGFR TP53
4	protein kinase binding	GO:0019901	9.77	AURKA CTNNB1 EGFR MSH2 TP53
5	protein phosphatase binding	GO:0019903	9.58	CTNNB1 EGFR TP53
6	enzyme binding	GO:0019899	9.55	CTNNB1 EGFR MLH1 MSH2 TP53
7	mismatched DNA binding	GO:0030983	9.43	MLH1 MSH2
8	chromatin binding	GO:0003682	9.43	CTNNB1 EGFR MLH1 MSH2 SATB2 TP53
9	guanine/thymine mispair binding	GO:0032137	9.32	MLH1 MSH2
10	nucleotide binding	GO:0000166	9.1	AURKA BRAF EGFR HRAS KRAS PIM2

Sources

Sources for Colorectal Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia